021-51111890
购物车（）
sales@molnova.cn
CL-82198
CAS No. 307002-71-7
CL-82198 ( —— )
产品货号. M24236 CAS No. 307002-71-7
CL-82198 是 MMP-13 的选择性抑制剂，是一种预防骨关节炎 (OA) 进展的化合物治疗方法。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥240 | 有现货 |
|
| 5MG | ￥391 | 有现货 |
|
| 10MG | ￥656 | 有现货 |
|
| 25MG | ￥1376 | 有现货 |
|
| 50MG | ￥2223 | 有现货 |
|
| 100MG | ￥3591 | 有现货 |
|
| 200MG | ￥5121 | 有现货 |
|
| 500MG | ￥7641 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥430 | 有现货 |
|
生物学信息
-
产品名称CL-82198
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述CL-82198 是 MMP-13 的选择性抑制剂，是一种预防骨关节炎 (OA) 进展的化合物治疗方法。
-
产品描述CL-82198 is a selective inhibitor of MMP-13 and it is a pharmacologic treatment for preventing osteoarthritis (OA) progression. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs.
-
体外实验——
-
体内实验Animal Model:10-week-old C57BL/6J mice (performed MLI surgery)Dosage:1, 5, 10 mg/kg body weight Administration:Intraperitoneal injection; every other day for 12 weeks Result:Prevented and decelerated MLI-induced osteoarthritis progression.
-
同义词——
-
通路Metabolic Enzyme/Protease
-
靶点MMP
-
受体MMP-13
-
研究领域——
-
适应症——
化学信息
-
CAS Number307002-71-7
-
分子量302.37
-
分子式C17H22N2O3
-
纯度>98% (HPLC)
-
溶解度DMSO:100 mg/mL (330.72 mM; Need ultrasonic)
-
SMILESO=C(c1cc(cccc2)c2o1)NCCCCN1CCOCC1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Rath T et al. Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett. 2011 May;2(3):483-488.
